SOMERSET, N.J., Nov. 5, 2015 /PRNewswire/ -- Meda Pharmaceuticals (Meda), a leading international specialty pharmaceutical company, announces the launch of Part 3 of the Medikidz Explain Asthma Series, the latest comic book to help families gain an accurate understanding of asthma. Medikidz Explain Asthma Part 3 is the third installment of a series of books developed for children with asthma and their families in collaboration with Medikidz, a global organization that produces unique learning materials for children in a powerfully visual comic book format. It follows Savion, age 10, on an epic journey through Mediland, as he gets a firsthand view of the science behind asthma.
“Our goal for the series is to engage kids and help them better understand and manage their asthma as well as overcome challenges associated with this chronic health condition,” said Stuart Loesch, Senior Vice President of Sales and Marketing, Meda. “We are committed to changing the patient landscape, by providing tools like Medikidz Explain Asthma for physicians to better connect with patients and families.”
Asthma is a common respiratory condition that affects 6.8 million children in the U.S. alone,1 according to the U.S. Centers for Disease Control and Prevention. It is characterized by difficulty breathing, wheezing, coughing and shortness of breath.
Medikidz comic books are written and reviewed by physician specialists to help families gain an accurate understanding of medical information. The action adventure world of its superhero characters helps explain illnesses and treatments to children. The Medikidz Explain Asthma series was developed in partnership with, and endorsed by, leading asthma and healthcare organizations.
“Medikidz Explain Asthma helps kids understand their asthma in a truly unique way, on a level they can understand and relate to. When kids have a better understanding about what’s happening in their body, they begin to approach the way they manage their asthma in a whole new way,” said Autumn Burnette, MD, Assistant Professor in the Division of Allergy and Immunology at Howard University Hospital. “They self-advocate more and become more of a partner in their care along with their healthcare provider. The series is a remarkable tool for educating and empowering kids with chronic asthma.”
Ordering the Comic Books
Healthcare providers can visit www.explainasthma.com to order their copies. Patients and caregivers can request a free copy directly from their provider.
In addition, attendees at the American College of Allergy, Asthma, and Immunology (ACAAI) 2015 Annual Scientific Meeting, held November 5-9, in San Antonio, TX, will get a first look at Medikidz Explain Asthma Part 3 and also have a chance to meet some of the Medikidz firsthand. Copies will be available to registered meeting attendees.
About Meda Pharmaceuticals
Meda is a leading international specialty pharma company with a broad product portfolio and its own sales organizations in almost 60 countries. Including those markets where sales are managed by distributors, Meda’s products are sold in more than 120 different countries. Meda’s product portfolio is divided into three main areas: specialty products, OTCs (nonprescription products and dietary supplements) and branded generics. In the United States, Meda has a strong history in respiratory innovation, with a focus in allergy and asthma.
Medikidz is a children’s medical education organization that works closely with healthcare professionals, advocacy groups, families, children and patients to produce unique learning materials in an interactive, powerfully-visual comic book format, thereby helping to educate children about their health as well as the health of those around them.
All content is written by physicians and peer-reviewed by leading specialists/key opinion leaders in the pertaining therapeutic area and endorsed by patient advocacy groups/professional organizations.
For further inquiries, please contact:
Candace Disler, Media Relations Manager, Green Room Communications, email@example.com
Phone: 973-263-8585, ext. 228